Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Cronos Group Inc.
CRON
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $1.1B
$2.86
▲ 0.00%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$1.93 - $3.43
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 43.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Diversified brand portfolio across hemp and cannabis segments
- Vertically integrated operations from cultivation to retail
- Established distribution network across e-commerce, retail, and wholesale channels
- International export capabilities and global market presence
Bear Case
2 risks
- Average volatility.
- High premium - requires strong execution
Growth
Turning profitable
Expanding legal cannabis market adoption across North America
Value
High premium - requires strong execution
Momentum
Strong
+13.0% over 3m
Quality
Strong
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying CRON right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 6, 2026
MAY 11, 2026
Reported EPS of $0.01 vs $0.01 consensus (0.0% surprise). Revenue of $45.2M vs $42.2M expected (+7.1%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
0.0%
Next: Aug 6, 2026
Revenue trend · last 8Q
—
—
—
+28%
+21%
+6%
+201%
+38%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$27.8M
$34.3M
$30.3M
$32.3M
$33.5M
$36.3M
$91.3M
$44.6M
Margins · last 8Q
Gross
—
Operating
—
Profit
30.4%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
No analyst coverage on file for this stock yet.